Spots Global Cancer Trial Database for precision oncology
Every month we try and update this database with for precision oncology cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | NCT06366451 | Head and Neck S... | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | NCT04786600 | Metastatic Colo... | Signatera ctDNA... pre-specified s... | 18 Years - 99 Years | University of Florida | |
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | NCT04683939 | Solid Tumor Gastric Cancer Gastroesophagea... Esophageal Aden... Pancreatic Canc... Biliary Tract C... Cholangiocarcin... Metastatic Canc... | BNT141 Nab-paclitaxel Gemcitabine | 18 Years - | BioNTech SE | |
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences | |
Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer | NCT02008994 | Metastatic Brea... | Genomic and Pro... | 18 Years - | Sanford Health | |
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | NCT04541108 | Solid Tumor | Rilvegostomig Volrustomig Sabestomig Pembrolizumab | 18 Years - | Presage Biosciences | |
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia | NCT04891718 | Solid Tumour | MVC-101 Nivolumab MVC-101 + Nivol... | 18 Years - | Presage Biosciences | |
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | NCT06062602 | Head and Neck S... | TAK-676 Carboplatin 5-FU Paclitaxel TAK-676 + Carbo... Carboplatin + P... Carboplatin + 5... TAK-676 + Carbo... TAK-676 + Carbo... | 18 Years - | Presage Biosciences | |
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma | NCT03056599 | Soft Tissue Sar... | Multiple drug m... CIVO device | 18 Years - | Presage Biosciences | |
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | NCT04065555 | Head and Neck C... | TAK-981 Cetuximab Avelumab TAK-981 + Cetux... TAK-981 + Avelu... | 18 Years - | Presage Biosciences |